MedTrace Logo

Assessment of LCZ696 and Valsartan in Asian Patients With Salt-sensitive Hypertension

NCT01681576 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2015-11-10

Study results available
· View outcomes & findings →

Summary

This study will evaluate the effect of LCZ696 and valsartan on natriuresis, diuresis, and blood pressure in salt-sensitive Asian hypertensive patients.

Conditions

  • Salt-sensitive Hypertension

Interventions

DRUG

Valsartan

Valsartan 320mg tablet once daily

DRUG

LCZ696

LCZ696 400mg tablet once daily

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-08-31
Primary Completion
2013-10-31
Completion
2013-10-31

Countries

  • United States
  • Hong Kong
  • Singapore
  • South Korea
  • Taiwan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01681576 on ClinicalTrials.gov